OmniComm Systems, Inc. Responds to Industry's Growing Demand for Integrated Electronic Data Capture (EDC) Solutions and Signs 15 New Deals in Second Quarter 2007
OmniComm Systems, Inc. Responds to Industry's Growing Demand for Integrated Electronic Data Capture (EDC) Solutions and Signs 15 New Deals in Second Quarter 2007
FT. LAUDERDALE, FL, July 23, 2007-/MarketWire/-OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that they have closed 15 new business deals in Q2, 2007. Key market segments for the new business include pharmaceutical, medical device, contract research organizations (CRO) and academic medical center customers, including a high profile Top 50 pharmaceutical company. TrialMaster will be implemented in both an ASP, fully hosted environment for the new trials and also in 2 new Technology Transfer deployments for those clients that want to bring EDC in-house.
OmniComm’s Sr. Vice President of Business Development, Stephen Johnson, commented, “The company’s escalating growth is a direct result of the drug development industry’s need for flexible and integrated solutions for clinical trials. TrialMaster provides sponsors with a feature rich EDC product that is easy to use, easy to integrate with and is not laden with hidden or exorbitant costs.” Added Johnson, “Our Support and Consulting Services groups are made up of industry veterans that stand ready to deliver quality driven solutions and support for our customers using EDC.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
